Xenon Pharmaceuticals
XENE
209 hedge funds and large institutions have $2.99B invested in Xenon Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 69 reducing their positions, and 21 closing their positions.
5,216% more call options, than puts
Call options by funds: $4.36M | Put options by funds: $82K
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
3% more funds holding
Funds holding: 203 → 209 (+6)
1.24% more ownership
Funds ownership: 98.84% → 100.08% (+1.2%)
1% more capital invested
Capital invested by funds: $2.95B → $2.99B (+$41.3M)
4% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.1M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.2M |
| 3 |
JP Morgan Chase
New York
|
+$15.7M |
| 4 |
SC
Stempoint Capital
New York
|
+$15.5M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$16.3M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$16M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.1M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$14.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$12.2M |
XENE Hedge Fund Activity: Q4 2024 in Review
209 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2024, worth a combined $2.99B — up 1.4% from $2.95B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new XENE positions and 21 closed out — a net gain of 8 holders — while 66 added to existing stakes and 69 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.1M. The largest seller was Citadel Advisors, cutting an estimated $16.3M.
- 209 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2024, up from 203 in Q3 2024.
- Funds reported $2.99B of Xenon Pharmaceuticals stock for Q4 2024, up 1.4% quarter-over-quarter.
- 29 funds opened new Xenon Pharmaceuticals positions in Q4 2024 and 21 closed out, a net change of +8 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $25.1M added.
- The largest Xenon Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $16.3M sold.
Based on aggregated 13F filings for Q4 2024.